Command Palette

Search for a command to run...

ABBOTINDIA

30095-0.12%
Market Cap
₹64,121.36 Cr
Stock P/E
0.00
ROCE
49.12%
ROE
37.45%
Book Value
₹0.00

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Institution
Public
Others

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Leader

Abbott India Ltd. stands out in the Pharmaceuticals & Drugs sector with remarkable profitability metrics, although its growth indicators are currently stagnant. It showcases the highest ROE and ROCE among peers, making it a strong candidate despite its high valuation. Companies like Cipla and Dr. Reddy's present robust growth and valuation metrics, while others like Sun Pharma are showing signs of being overvalued due to high P/E ratios.

Key Points
  • Abbott India boasts the highest ROE (37.45%) and ROCE (49.12%) among peers.
  • Cipla shows the strongest revenue growth (YoY: 13.28%) with favorable valuation metrics (PE: 23.73).
  • Sun Pharmaceutical is overvalued with a PE of 87.59 despite moderate growth metrics.
Top Performers
Abbott India Ltd.

Highest ROE (37.45%) and ROCE (49.12%) indicating strong profitability.

Cipla Ltd.

Strong revenue growth (YoY: 13.28%) with attractive valuation (PE: 23.73).

Dr. Reddy's Laboratories Ltd.

Solid revenue growth (16.54% YoY) and low PE (15.50) making it highly attractive.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.